0001127602-23-017338.txt : 20230601
0001127602-23-017338.hdr.sgml : 20230601
20230601160020
ACCESSION NUMBER: 0001127602-23-017338
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230531
FILED AS OF DATE: 20230601
DATE AS OF CHANGE: 20230601
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NABEL ELIZABETH G
CENTRAL INDEX KEY: 0001619929
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39348
FILM NUMBER: 23984585
MAIL ADDRESS:
STREET 1: BRIGHAM AND WOMEN'S HOSPITAL
STREET 2: 75 FRANCIS ST
CITY: BOSTON
STATE: MA
ZIP: 02115
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Accolade, Inc.
CENTRAL INDEX KEY: 0001481646
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389]
IRS NUMBER: 432117836
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0228
BUSINESS ADDRESS:
STREET 1: 660 W. GERMANTOWN PIKE SUITE 500
CITY: PLYMOUTH MEETING
STATE: PA
ZIP: 19462
BUSINESS PHONE: 610-834-2989
MAIL ADDRESS:
STREET 1: 660 W. GERMANTOWN PIKE SUITE 500
CITY: PLYMOUTH MEETING
STATE: PA
ZIP: 19462
FORMER COMPANY:
FORMER CONFORMED NAME: Accolade LLC
DATE OF NAME CHANGE: 20100121
4
1
form4.xml
PRIMARY DOCUMENT
X0407
4
2023-05-31
0001481646
Accolade, Inc.
ACCD
0001619929
NABEL ELIZABETH G
C/O ACCOLADE, INC.
1201 THIRD AVENUE, SUITE 1700
SEATTLE
WA
98101
1
0
Common Stock
2023-05-31
4
M
0
1752
A
4757
D
Restricted Stock Units
2023-05-31
4
M
0
1752
D
Common Stock
1752
5254
D
Each Restricted Stock Unit ("RSU") converted into one share of Common Stock upon vesting of the RSU.
Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU.
The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2023 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date.
/s/ Richard Eskew, Attorney-in-Fact
2023-06-01